Health Technology Healios KK Business Summary
Healios KK engages in the research, development, and sale of cellular and regenerative medicine. It develops therapies for ischemic stroke, acute respiratory distress syndrome, liver disease, and age-regulated macular degeneration. The company was founded by Tadahisa Kagimoto on February 24, 2011 and is headquartered in Tokyo, Japan.
Financial Highlights
Dec 2020
JPY USD Revenue 27M 0.25M Gross Profit -- -- Operating income -4,198M -39.31M Income before tax -5,364M -50.23M Net income -5,512M -51.62M EBITDA -3,969M -37.17M Diluted EPS -107.19 -1.00 Dividends Per Share 0 0 Total Assets 23,171M 224.42M Total liabilities 15,320M 148.38M Total equity 7,844M 75.97M Operating cash flow -3,945M -36.94M Currency in JPY Currency in USD
Historical Data Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Revenue
77.64M
27.66M
0
89M
27M
Gross Profit
-100.81M
-75.96M
-78M
--
--
Operating income
-3,507.46M
-2,348.20M
-5,063M
-4,281M
-4,198M
Income before tax
-3,426.74M
-1,771.55M
-5,091M
-4,547M
-5,364M
Net income
-3,433.55M
-1,776.65M
-5,097M
-4,806M
-5,512M
EBITDA
-3,338.15M
-2,247.89M
-4,985M
-4,140M
-3,969M
Diluted EPS
-84.33
-39.73
-103.51
-95.85
-107.19
Dividends Per Share
0
0
0
0
0
Total Assets
9,174.98M
19,696.42M
14,980M
25,594M
23,171M
Total liabilities
3,180.55M
3,532.74M
4,196M
13,250M
15,320M
Total equity
5,994.42M
16,163.67M
10,782M
12,335M
7,844M
Operating cash flow
-3,782.67M
-1,762.18M
-5,148M
-4,859M
-3,945M
Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Revenue
0.71M
0.24M
0
0.81M
0.25M
Gross Profit
-0.92M
-0.67M
-0.70M
--
--
Operating income
-32.27M
-20.94M
-45.84M
-39.27M
-39.31M
Income before tax
-31.53M
-15.79M
-46.09M
-41.71M
-50.23M
Net income
-31.59M
-15.84M
-46.15M
-44.08M
-51.62M
EBITDA
-30.72M
-20.04M
-45.13M
-37.97M
-37.17M
Diluted EPS
-0.77
-0.35
-0.93
-0.87
-1.00
Dividends Per Share
0
0
0
0
0
Total Assets
78.66M
174.84M
136.53M
235.50M
224.42M
Total liabilities
27.26M
31.36M
38.24M
121.92M
148.38M
Total equity
51.39M
143.48M
98.27M
113.50M
75.97M
Operating cash flow
-34.81M
-15.71M
-46.61M
-44.57M
-36.94M
Valuation Measures
Dec 2020
PER -- ROA -22.60% ROE -54.63% Operating margin -15,548.14% Profit margin -20,414.81%
Key executives
President, Chief Executive Officer & Director:
Hardy T. S. Kagimoto
Chief Financial Officer & Director:
Richard Patrick Kincaid
Chief Medical Officer & Executive Vice President:
Masanori Sawada
Executive Officer, Head-Research & Production Area:
Kouichi Tamura
Executive Officer & Head-Development Area:
Michihisa Nishiyama Shareholders
KAGIMOTO HARDY T S (54.8%)
Baillie Gifford & Co. (4.0%)
Asset Management One Co., Ltd. (3.8%)
Nikon Corp. (2.9%)
Sumitomo Dainippon Pharma Co., Ltd. (2.8%)
Matthews International Capital Management LLC (2.4%)
JPMorgan Asset Management (Japan) Ltd. (2.3%)
FUJIOKA YOSHIHISA (1.3%)
Nomura Asset Management Co., Ltd. (1.1%)
FIL Investment Management (Hong Kong) Ltd. (0.8%)
Related Companies
Healios N.A., Inc.
Sighregen Co., Ltd.
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 24 Jun, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
